United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 7 minute read General business news Santander UK delays Q3 2025 results as bond market watches FCA redress fallout and CEO exit Santander UK delays Q3 2025 results citing FCA redress uncertainty, while bond markets remain confident and CEO Regnier plans exit by Q1 2026. byVenkateshOctober 30, 2025